Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment

PURPOSE: Immunotherapy has recently been shown to improve outcomes for advanced PD-L1-positive triple-negative breast cancer (TNBC) in the Impassion130 trial, leading to FDA approval of the first immune checkpoint inhibitor in combination with taxane chemotherapy. To further develop predictive bioma...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Breast Cancer Res Treat
Autori principali: Deng, Jiehui, Thennavan, Aatish, Shah, Suhagi, Bagdatlioglu, Ece, Klar, Natalie, Heguy, Adriana, Marier, Christian, Meyn, Peter, Zhang, Yutong, Labbe, Kristen, Almonte, Christina, Krogsgaard, Michelle, Perou, Charles M., Wong, Kwok-Kin, Adams, Sylvia
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2020
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8170702/
https://ncbi.nlm.nih.gov/pubmed/32949350
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-020-05936-4
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi